Central Nervous System News and Research

RSS

Bionomics begins BNC210 Phase II clinical trial for treatment of anxiety, depression

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of cancer and diseases of the central nervous system, today announced the initiation of a Phase II clinical study of BNC210, the Company's drug candidate in development for the treatment of anxiety and depression.

20 Apr 2015

Toxic Botox travels through our nerves to reach central nervous system

New research might bring a frown to even the most heavily botoxed faces, with scientists finding how some of the potent toxin used for cosmetic surgery escapes into the central nervous system.

17 Apr 2015

Inflammation plays causal role in neurologic changes associated with Lyme disease

About 15% of patients with Lyme disease develop peripheral and central nervous system involvement, often accompanied by debilitating and painful symptoms. New research indicates that inflammation plays a causal role in the array of neurologic changes associated with Lyme disease, according to a study published in The American Journal of Pathology.

17 Apr 2015

Study could lead to new therapeutic targets for treating Huntington's disease

An international study led by researchers from Université Laval and CHU de Québec-Université Laval has identified significant vascular changes in the brains of people with Huntington's disease. This breakthrough, the details of which are published in the most recent issue of Annals of Neurology, will have significant implications for our understanding of the disease and could open the door to new therapeutic targets for treating this fatal neurodegenerative condition.

17 Apr 2015

Lack of fish oil fatty acids can limit brain growth during fetal development and early in life

While recent reports question whether fish oil supplements support heart health, UC Irvine scientists have found that the fatty acids they contain are vitally important to the developing brain.

16 Apr 2015

SELLAS inks exclusive global collaboration, license agreement with TrojanTec

SELLAS Life Sciences Group, a Swiss based, development-stage biopharmaceutical company with its main focus in developing innovative products for the treatment of various indications in Oncology and the Central Nervous System, today announced that it has signed an exclusive global collaboration and license agreement with TrojanTec Ltd, a UK-based Discovery Research and Development Company affiliated with Imperial College London, UK, for the development, marketing and commercialization of the innovative and proprietary TR-1 cancer therapeutic technology and drug.

15 Apr 2015

Cantab Connect CTIS-Abuse Liability product exceeds $1.5m sales in first 9 months

Cambridge Cognition Holdings plc,the developer of cognitive assessment software, announces that sales of Cantab Connect CTIS-Abuse Liability have exceeded £1m in its first 9 months from launch.

15 Apr 2015

Nielsen BioSciences launches skin test that helps physicians manage Valley Fever infections

Nielsen BioSciences announced today the launch of SPHERUSOL (Coccidioides immitis Spherule-Derived Skin Test Antigen), a skin test that provides valuable data to physicians managing Valley Fever infections. SPHERUSOL has been approved by the U.S. Food and Drug Administration as the only skin test to detect an immune response to the fungus called Coccidioides, or "cocci," in patients with history of the disease.

9 Apr 2015

Frost & Sullivan forecasts growth of global healthcare market

The healthcare industry is entangled in a transitory phase in which therapeutics, devices, products and services are sold into traditional care settings that are unable to keep up with the requirements placed upon it by changing demographics and consumer needs. At the same time, opportunities for new services and care, such as ambulatory, mobile, and home care, lack the appropriate level of maturity to provide robust revenue streams despite having the promise to increase healthcare delivery efficiency and reduce long term costs.

8 Apr 2015

AACN announces recipients of annual research grants

The American Association of Critical-Care Nurses announces the recipients of its annual research grants, with total available funding of $160,000.

8 Apr 2015

Study identifies genetic variants linked to Hirschsprung’s disease

Genetic studies in humans, zebrafish and mice have revealed how two different types of genetic variations team up to cause a rare condition called Hirschsprung’s disease. The findings add to an increasingly clear picture of how flaws in early nerve development lead to poor colon function, which must often be surgically corrected.

8 Apr 2015

Study reveals how cell's protein quality control mechanism helps combat neurodegenerative diseases

A molecular pathway known to suppress tumors appears to also be a major player in clearing cells of damaged proteins implicated in neurodegenerative diseases such as ALS and certain types of dementia, new research in roundworms and human cells suggests.

6 Apr 2015

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Depomed, Inc. today announced that it has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes: NUCYNTA ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment; NUCYNTA (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults; and NUCYNTA (tapentadol) oral solution, an approved oral form of tapentadol that has not been launched.

6 Apr 2015

Peripheral inflammatory cells play role in Parkinson's disease

A small area in the midbrain known as the substantia nigra is the control center for all bodily movement. Increasing loss of dopamine-generating neurons in this part of the brain therefore leads to the main symptoms of Parkinson's disease - slowness of movement, rigidity and shaking.

3 Apr 2015

Omeros announces commercial availability of Omidria in U.S.

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, announced today the nationwide commercial availability of Omidria (phenylephrine and ketorolac injection) 1%/0.3%.

2 Apr 2015

Idiopathic central precocious puberty on the rise in boys

About three-quarters of cases of central precocious puberty in boys have no identifiable cause, say researchers.

1 Apr 2015

Research breakthrough could help develop tools to repair damaged nerve cells

A team of researchers at the IRCM led by Frédéric Charron, PhD, in collaboration with bioengineers at McGill University, uncovered a new kind of synergy in the development of the nervous system, which explains an important mechanism required for neural circuits to form properly.

1 Apr 2015

MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

Nektar Therapeutics reported that partner AstraZeneca announced today that MOVANTIK (naloxegol) has launched in the United States. On September 16, 2014, the US Food and Drug Administration (FDA) approved MOVANTIK as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain.

31 Mar 2015

China Pharma's revenue decreases 24% to $24.9 million in fiscal year 2014

China Pharma Holdings, Inc., an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the year ended December 31, 2014.

31 Mar 2015

Study provides insights into basis for cognitive dysfunction

Scientists at Columbia University's Mailman School of Public Health have identified a unique pattern of immune molecules in the cerebrospinal fluid of people with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) that provides insights into the basis for cognitive dysfunction--frequently described by patients as "brain fog"--as well as new hope for improvements in diagnosis and treatment.

31 Mar 2015

Central Nervous System News and Research

Bionomics begins BNC210 Phase II clinical trial for treatment of anxiety, depression

Toxic Botox travels through our nerves to reach central nervous system

Inflammation plays causal role in neurologic changes associated with Lyme disease

Study could lead to new therapeutic targets for treating Huntington's disease

Lack of fish oil fatty acids can limit brain growth during fetal development and early in life

SELLAS inks exclusive global collaboration, license agreement with TrojanTec

Cantab Connect CTIS-Abuse Liability product exceeds $1.5m sales in first 9 months

Nielsen BioSciences launches skin test that helps physicians manage Valley Fever infections

Frost & Sullivan forecasts growth of global healthcare market

AACN announces recipients of annual research grants

Study identifies genetic variants linked to Hirschsprung’s disease

Study reveals how cell's protein quality control mechanism helps combat neurodegenerative diseases

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Peripheral inflammatory cells play role in Parkinson's disease

Omeros announces commercial availability of Omidria in U.S.

Idiopathic central precocious puberty on the rise in boys

Research breakthrough could help develop tools to repair damaged nerve cells

MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

China Pharma's revenue decreases 24% to $24.9 million in fiscal year 2014

Study provides insights into basis for cognitive dysfunction

Event guide: The 7th CNS Drug Delivery Summit eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News